Document Detail


Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates.
MedLine Citation:
PMID:  17600479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to evaluate adverse and therapeutic effects of applicated holmium-boro-macroaggregates (HBMAs) in the radiosynoviorthesis (RSO) of knees in patients suffering from chronic synovitis. We started RSO of the knees by means of a new radiopharmaceutical (RF) HBMA in patients with gonarthrosis, rheumatoid arthritis, chronic synovitis, psoriatic arthritis, and gout arthropathy. Seventeen (17) intra-articular injections were performed in 15 patients who were receiving a mean activity of 972 MBq (range, 904-1057) of 166Ho-HBMA. Patient inclusion to the study followed a series of inclusion and exclusion criterions. The patients were hospitalized for 3 days. Side-effects were evaluated during their hospital stay and again after 6-8 weeks. Static scintigraphy of knee joints and measurements of blood radioactivity were performed. Therapeutic effects were evaluated after 6-8 weeks and at 6 months. In 2 hours and 2 days following the application, we proved, by means of knee and inguinal scintigraphy, only insignificant radiopharmaceutical leakage from the joint cavity to the inguinal lymph nodes in 4 patients. In the treated patients, no serious adverse effects occurred. Nine (9) patients were without complaints, 4 patients had slight knee exudation, and 2 patients had great exudation. Therapeutic effects were as follows: 2 patients were without pain, 9 were with lower pain, 3 were with the same pain, and 1 patient was with increased pain. Joint motion was improved in 7 patients, remained the same in 7 patients, and was impaired in 1 patient. Analgesics consumption was lower in 5 patients, the same in 9 patients, and greater in 1 patient. Knee exudation was absent in 2 patients, lower in 4 patients, the same in 6 patients, and greater in 3 patients. In 3 patients it was necessary to do surgical RSO. This RF can extend the range of clinically used radiopharmaceuticals for RSO and to supplement space between 90Y with high energy and 186Re with 169Er with lower beta energy. The energy of 166Ho is suitable for great and medium joints (i.e., knees, hips, shoulders, elbows, wrists, and ankles).
Authors:
Otakar Kraft; Richard Kaspárek; Vojtech Ullmann; Frantisek Melichar; Martin Kropácek; Marcela Mirzajevova
Related Documents :
3467689 - Reiter's syndrome: chronicity of symptoms and employment.
12453269 - Analysis of post-treatment electromyographs in patients with non-reducing disc displace...
7606419 - Destructive arthropathy of the hands in chronic hemodialysis patients. a report of seve...
8379839 - Exercise therapy effects on functional radiographic findings and segmental electromyogr...
7932429 - Henoch-schönlein purpura in rheumatoid arthritis.
15995119 - Early osteolysis following second-generation metal-on-metal hip replacement.
2055079 - Risk factors for the misdiagnosis of pneumothorax in the intensive care unit.
24605889 - Utility of foramen ovale electrodes in mesial temporal lobe epilepsy.
17532409 - Absence of correlation between symptoms and rhythm in "symptomatic" atrial fibrillation.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cancer biotherapy & radiopharmaceuticals     Volume:  22     ISSN:  1084-9785     ISO Abbreviation:  Cancer Biother. Radiopharm.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-06-29     Completed Date:  2007-09-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9605408     Medline TA:  Cancer Biother Radiopharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  296-302     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, University Hospital, Ostrava-Poruba, Czech Republic. otakar.kraft@fnspo.cz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Female
Holmium / adverse effects,  therapeutic use*
Humans
Knee / pathology*,  radiation effects*
Male
Middle Aged
Synovitis / pathology*,  radiotherapy*
Time Factors
Chemical
Reg. No./Substance:
7440-60-0/Holmium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in resp...
Next Document:  Antibiotic resistance in bacteria associated with food animals: a United States perspective of lives...